


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

POSITIVE PROFIT ALERT

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of the directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) wishes to inform the shareholders of the Company and the potential investors that, based on the unaudited consolidated management accounts of the Company for the six months ended 30 June 2017 prepared in accordance with Hong Kong Financial Reporting Standards, the Group’s unaudited interim results for the six months ended 30 June 2017 is expected to record a profit of approximately RMB100,000,000, while the loss for the six months ended 30 June 2016 is approximately RMB13,000,000.

Turning from loss to profit is mainly attributable to (i) increase in sales of intermediate and bulk medicine products; (ii) the utilization of production capacity of the Inner Mongolia plant increased resulting in reduction of production cost. Segmental results of intermediate and bulk medicine products are substantially improved as compared with same period last year; (iii) increase in gain on fair value change of embedded derivative components of convertible bonds; and (iv) the loss on fair value change on investment properties being offset.

The information in this announcement is only based on the information currently available to the management. The results of the Group for the six months ended 30 June 2017 have not yet been finalized nor reviewed by the Company’s audit committee and auditor. The final results of the Group for the six months ended 30 June 2017 may be different to the information referred in this announcement.

Detailed unaudited interim results of the Group for the six months ended 30 June 2017 will be published in the forthcoming 2017 interim results announcement and interim report of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
**The United Laboratories
International Holdings Limited**
Tsoi Hoi Shan
Chairman

Hong Kong, 17 August 2017

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Ms. Zou Xian Hong, Ms. Zhu Su Yan and Mr. Fang Yu Ping as executive directors; and Mr. Chong Peng Oon, Mr. Huang Bao Guang, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.